A compelling paradigm is forming in which dapagliflozin can be prescribed not only to prevent heart failure in people with type 2 diabetes, but also in the patients without diabetes, said Kiersten Combs, US vice president of Cardiovascular Metabolism at AstraZeneca.
A compelling paradigm is forming in which dapagliflozin can be prescribed not only to prevent heart failure in people with type 2 diabetes, but also in the patients without diabetes, said Kiersten Combs, US vice president of Cardiovascular Metabolism at AstraZeneca.
Transcript
The focus of the presentations at this year’s American Heart Association meeting is how dapagliflozin can offer protection against worsening of heart failure even in patients who do not have diabetes. The initial results released in Paris [at the European Society of Cardiology] showed that these benefits were nearly identical in patients with and without diabetes. How have payers responded to these data?
We’re extremely excited about our presence here across our cardiovascular metabolic portfolio, but specifically, to your point, the DAPA-HF data and some cut analysis that we’re reading out here is quite compelling. To your point, both in what you see in the heart failure composite endpoint, a 27% relative risk reduction in non-diabetic patients and a 25% relative risk reduction in the diabetic patient. From a payer perspective, since we introduced this data in Paris, we have taken it and talked to many of our payers, and just as the scientific community has been extremely excited about this data, we are seeing the same positive response from payers.
The recent study in JAMA Cardiology shows that heart failure is increasing in the US population. How can the findings from DAPA-HF translate into a broad-based solution for at-risk patients?
I think not only in heart failure patients, but also when you look at the data that’s in DECLARE [DECLARE-TIMI] that shows in type 2 diabetic patients that we can prevent the hospitalization of heart failure. When you put those together, there is a really compelling paradigm shifting science that suggests that as this goes through the regulatory process, we could be in a place where Farxiga [dapagliflozin] can not only prevent heart failure in type 2 diabetics, but then also treat both in the diabetic and non-diabetic patient population.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More